Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz
Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis pattern...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
FUTURE MEDICINE LTD
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/626506 http://arizona.openrepository.com/arizona/handle/10150/626506 |